G6PD activator AG1 is a glucose-6-phosphate dehydrogenase (G6PD) agonist that promotes glucose-6-phosphate dehydrogenase (G6PD) oligomerization to a catalytically competent form. G6PD activator AG1 reduces oxidative stress in cells and zebrafish, reduces chloroquine or diamide-induced oxidative stress in human erythrocytes, and can be used to study glucose-6-phosphate dehydrogenase deficiency.

G6PD:3 µΜ

G6PD activator AG1 (1-5 μΜ; pre-incubated overnight) reduces the extent of hemolysis with 5 μΜ in human erythrocytes suspension (5%) exposed to either 1 mM chloroquine (CQ; 4 hours) or diamide (a GSH oxidant; 4 hours). G6PD activator AG1 increases GSH levels and reduced ROS levels together with increased G6PD activity under these drug-induced oxidative stress. [1]
G6PD activator AG1 (50, 100, 250, 500, 750, 1000 nM) increases the viability by 20% and the proteolytic stability of Canton G6PD in SH-SY5Y cells. G6PD activator AG1 has no effect when G6PD was knocked down by siRNA, supporting the specificity of G6PD activator AG1 toward G6PD. [1]